Spojené státy - angličtina - NLM (National Library of Medicine)

avera mckennan hospital - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine 15 mg

Spojené státy - angličtina - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.

Spojené státy - angličtina - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.

Kanada - angličtina - Health Canada

sanofi-aventis canada inc - primaquine phosphate - tablet - 26.3mg - primaquine phosphate 26.3mg - antimalarials

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - primaquine phosphate, quantity: 13.2 mg (equivalent: primaquine, qty 7.5 mg) - tablet, uncoated - excipient ingredients: wheat starch; povidone; purified water; lactose monohydrate; purified talc; gelatin; magnesium stearate; glycerol - prevention of relapses (radical cure) of malaria caused by p.vivax and p. ovale. adjunctive therapy in the treatment of gametocytemia due to p.falciparum in patients resident in areas receptive to malaria.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

astrazeneca limited - primaquine phosphate 7.5mg - tablet - 7.5 mg - active: primaquine phosphate 7.5mg

Malajsie - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaniaga manufacturing berhad - primaquine phosphate -

Spojené státy - angličtina - NLM (National Library of Medicine)

bluebay shandong co.,ltd - primaquine phosphate (unii: h0982hf78b) (primaquine phosphate - unii:h0982hf78b) -

Filipíny - angličtina - FDA (Food And Drug Administration)

allied pharma'l labs inc - primaquine phosphate - tablet - 26.3mg

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - primaquine phosphate - oral tablet - 7.5mg